Eli Lilly is spending $9 billion to make the hard part of a drug in Indiana. The company’s campus in the LEAP Lebanon Innovation and Research District, north of Indianapolis in Boone County, is built to produce active pharmaceutical ingredients, the chemically complex core of a medicine that’s long been outsourced overseas. It’s one of the largest pharmaceutical manufacturing investments the US has seen.
Project Scope
The plan calls for roughly a dozen buildings and more than 1.6 million square feet across a 600-acre site, with the company’s total commitment in the district running past $13 billion once related work is counted. The build is split into packages: Fluor is running the first facility, Lebanon Project 1, while Jacobs and Cincinnati-based Messer Construction handle the second. At peak, around 4,500 craft workers are expected on site, and the full program is slated to take roughly four years. API plants are unforgiving work. The process equipment, cleanrooms and tight tolerances mean the construction sequence is dictated by the chemistry it will eventually house.
Why It Matters
The pandemic exposed how much of the drug supply chain runs through a handful of overseas plants, and reshoring that capacity has been a policy goal ever since. Lilly’s campus is one of the biggest physical answers to that question, and it’s the anchor that turned LEAP from a greenfield gamble into a real industrial district. The same site has drawn other giants, including Meta’s $10 billion data center campus, clustering pharma and hyperscale construction on the same Indiana farmland. For the trades, it’s years of high-spec work close to home.
Project Team & Details
| Developer | Eli Lilly and Company |
|---|
| Owner / Client | Eli Lilly and Company |
|---|
| General Contractor | Fluor (Lebanon Project 1); Jacobs / Messer Construction (Lebanon Project 2) |
|---|
| Status | Under Construction |
|---|
| Delivery Method | Design-Build |
|---|
| Funding Source | Private |
|---|
